CN117100836A - 一种灵芝益智仁海洋鱼低聚肽组合物及其在预防或治疗高尿酸症及抗疲劳的应用 - Google Patents
一种灵芝益智仁海洋鱼低聚肽组合物及其在预防或治疗高尿酸症及抗疲劳的应用 Download PDFInfo
- Publication number
- CN117100836A CN117100836A CN202311336501.2A CN202311336501A CN117100836A CN 117100836 A CN117100836 A CN 117100836A CN 202311336501 A CN202311336501 A CN 202311336501A CN 117100836 A CN117100836 A CN 117100836A
- Authority
- CN
- China
- Prior art keywords
- parts
- powder
- serum
- ganoderma lucidum
- marine fish
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 40
- 201000001431 Hyperuricemia Diseases 0.000 title claims abstract description 33
- 241000251468 Actinopterygii Species 0.000 title claims abstract description 28
- 240000008397 Ganoderma lucidum Species 0.000 title claims abstract description 28
- 235000001637 Ganoderma lucidum Nutrition 0.000 title claims abstract description 28
- 108010038807 Oligopeptides Proteins 0.000 title claims abstract description 28
- 102000015636 Oligopeptides Human genes 0.000 title claims abstract description 28
- 230000000694 effects Effects 0.000 claims abstract description 62
- 210000002966 serum Anatomy 0.000 claims abstract description 60
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims abstract description 42
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims abstract description 41
- 229940116269 uric acid Drugs 0.000 claims abstract description 41
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims abstract description 40
- 229940109239 creatinine Drugs 0.000 claims abstract description 20
- 108010093894 Xanthine oxidase Proteins 0.000 claims abstract description 16
- 102100033220 Xanthine oxidase Human genes 0.000 claims abstract description 16
- 239000003814 drug Substances 0.000 claims abstract description 14
- 230000000968 intestinal effect Effects 0.000 claims abstract description 14
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 claims abstract description 12
- 210000004185 liver Anatomy 0.000 claims abstract description 12
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 claims abstract description 11
- 108010082126 Alanine transaminase Proteins 0.000 claims abstract description 11
- 108010003415 Aspartate Aminotransferases Proteins 0.000 claims abstract description 9
- 102000004625 Aspartate Aminotransferases Human genes 0.000 claims abstract description 9
- 230000002265 prevention Effects 0.000 claims abstract description 8
- 239000000843 powder Substances 0.000 claims description 46
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 15
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 15
- 229940072205 lactobacillus plantarum Drugs 0.000 claims description 15
- 239000000284 extract Substances 0.000 claims description 12
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 10
- 241000572565 Alpinia oxyphylla Species 0.000 claims description 9
- 239000002304 perfume Substances 0.000 claims description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 235000013399 edible fruits Nutrition 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 6
- 244000163122 Curcuma domestica Species 0.000 claims description 5
- 235000003392 Curcuma domestica Nutrition 0.000 claims description 5
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 5
- 229920001353 Dextrin Polymers 0.000 claims description 5
- 239000004375 Dextrin Substances 0.000 claims description 5
- 240000007594 Oryza sativa Species 0.000 claims description 5
- 235000007164 Oryza sativa Nutrition 0.000 claims description 5
- 235000005805 Prunus cerasus Nutrition 0.000 claims description 5
- 244000207449 Prunus puddum Species 0.000 claims description 5
- 235000009226 Prunus puddum Nutrition 0.000 claims description 5
- 244000046101 Sophora japonica Species 0.000 claims description 5
- 235000010586 Sophora japonica Nutrition 0.000 claims description 5
- 229930003268 Vitamin C Natural products 0.000 claims description 5
- 235000003373 curcuma longa Nutrition 0.000 claims description 5
- 235000019425 dextrin Nutrition 0.000 claims description 5
- 235000013312 flour Nutrition 0.000 claims description 5
- 235000009566 rice Nutrition 0.000 claims description 5
- 235000013976 turmeric Nutrition 0.000 claims description 5
- 235000019154 vitamin C Nutrition 0.000 claims description 5
- 239000011718 vitamin C Substances 0.000 claims description 5
- 244000060011 Cocos nucifera Species 0.000 claims description 3
- 235000013162 Cocos nucifera Nutrition 0.000 claims description 3
- 240000007049 Juglans regia Species 0.000 claims description 3
- 235000009496 Juglans regia Nutrition 0.000 claims description 3
- 244000303379 Styrax officinalis Species 0.000 claims description 3
- 235000001361 Styrax officinalis Nutrition 0.000 claims description 3
- 239000001556 apium graveolens l. seed extract Substances 0.000 claims description 3
- 229940116732 celery seed extract Drugs 0.000 claims description 3
- 235000019382 gum benzoic Nutrition 0.000 claims description 3
- 239000001508 potassium citrate Substances 0.000 claims description 3
- 229960002635 potassium citrate Drugs 0.000 claims description 3
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 claims description 3
- 235000011082 potassium citrates Nutrition 0.000 claims description 3
- 238000004321 preservation Methods 0.000 claims description 3
- 239000001509 sodium citrate Substances 0.000 claims description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 3
- 235000020234 walnut Nutrition 0.000 claims description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 2
- 235000005976 Citrus sinensis Nutrition 0.000 claims description 2
- 240000002319 Citrus sinensis Species 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- 235000015165 citric acid Nutrition 0.000 claims description 2
- 229940105040 geranium extract Drugs 0.000 claims description 2
- 239000001630 malic acid Substances 0.000 claims description 2
- 235000011090 malic acid Nutrition 0.000 claims description 2
- 235000011083 sodium citrates Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 244000111489 Gardenia augusta Species 0.000 claims 2
- 239000012669 liquid formulation Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 11
- 230000002929 anti-fatigue Effects 0.000 abstract description 10
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 33
- 239000000047 product Substances 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 239000013641 positive control Substances 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 201000005569 Gout Diseases 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 238000012163 sequencing technique Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 108020004465 16S ribosomal RNA Proteins 0.000 description 4
- 240000001972 Gardenia jasminoides Species 0.000 description 4
- 206010018634 Gouty Arthritis Diseases 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- QARYADFHOUHDSW-UHFFFAOYSA-M potassium 2H-oxazine-3-carboxylate Chemical compound O1NC(=CC=C1)C(=O)[O-].[K+] QARYADFHOUHDSW-UHFFFAOYSA-M 0.000 description 4
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 3
- 229930024421 Adenine Natural products 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229960000643 adenine Drugs 0.000 description 3
- 238000012165 high-throughput sequencing Methods 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102000003929 Transaminases Human genes 0.000 description 2
- 108090000340 Transaminases Proteins 0.000 description 2
- 108010092464 Urate Oxidase Proteins 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000002550 fecal effect Effects 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000000528 statistical test Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229940005267 urate oxidase Drugs 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
- 108020004463 18S ribosomal RNA Proteins 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 244000298479 Cichorium intybus Species 0.000 description 1
- 235000007542 Cichorium intybus Nutrition 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 244000077995 Coix lacryma jobi Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 240000004638 Dendrobium nobile Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 244000268590 Euryale ferox Species 0.000 description 1
- 235000006487 Euryale ferox Nutrition 0.000 description 1
- 240000008672 Gynura procumbens Species 0.000 description 1
- 235000018457 Gynura procumbens Nutrition 0.000 description 1
- 206010021137 Hypovolaemia Diseases 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 244000046146 Pueraria lobata Species 0.000 description 1
- 235000010575 Pueraria lobata Nutrition 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 240000009022 Smilax rotundifolia Species 0.000 description 1
- 235000003205 Smilax rotundifolia Nutrition 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- FGUZFFWTBWJBIL-XWVZOOPGSA-N [(1r)-1-[(2s,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)O[C@H](CO)[C@H]1OC[C@H](O)[C@H]1O FGUZFFWTBWJBIL-XWVZOOPGSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940021973 bay leaf extract Drugs 0.000 description 1
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical group CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 229940078456 calcium stearate Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000013000 chemical inhibitor Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000816 effect on animals Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000001883 pimenta racemosa mill. fruit leaf extract Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 229940057429 sorbitan isostearate Drugs 0.000 description 1
- 229950004959 sorbitan oleate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
- 229940057977 zinc stearate Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/744—Gardenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9062—Alpinia, e.g. red ginger or galangal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明提供了一种灵芝益智仁海洋鱼低聚肽组合物及其在制备预防和/或治疗受试者高尿酸血症及抗疲劳的应用,属于高尿酸血症和/或疲劳的预防和治疗技术领域。本发明首次发现灵芝益智仁海洋鱼低聚肽组合物预防或治疗高尿酸血症及抗疲劳取得较好效果,治疗后小鼠血清尿酸(UA)、血清和肝脏黄嘌呤氧化酶活性(XOD)、血清肌酐(CRE)、血清尿素氮(BUN)、血清谷丙转氨酶(ALT)、血清谷草转氨酶(AST)水平等指标得到明显改善,同时能够调节高尿酸血症小鼠肠道菌群丰度,小鼠的抗疲劳能力增强。灵芝益智仁海洋鱼低聚肽组合物通过降尿酸以及肠道菌群调节等对高尿酸血症及疲劳有预防和或治疗作用,具有重大产业价值。
Description
技术领域
本发明属于高尿酸血症和/或疲劳的预防和治疗技术领域,具体涉及一种灵芝益智仁海洋鱼低聚肽组合物及其在预防或治疗高尿酸血症及抗疲劳的应用。
背景技术
高尿酸血症(HUA)是指在正常饮食状态下,体内尿酸生成过多和(或)排泄过少所致。非同日两次空腹血尿酸水平男性高于420μmol/L,女性高于360μmol/L,即称为高尿酸血症。尿酸是人类嘌呤化合物的终末代谢产物。嘌呤代谢紊乱导致高尿酸血症。患者可通过饮用随低食物和控制体重,达到缓解、治疗高尿酸血症的效果。
高尿酸血症已经成为继“三高”疾病之后的“第四高”,尿酸的主要排泄渠道就是肾脏,当尿酸值超过了肾脏的代谢极限,尿酸盐就会结晶沉淀在关节腔内,出现关节疼痛、关节红肿等症状,诱发痛风性关节炎。一般质量方法为物理治疗和药物治疗,物理治疗不能从根本上解决问题,只能缓解痛风症状;药物治疗容易产生耐药性和不良反应。
专利CN202110500995.8公开了一种降尿酸促进痛风石溶解的制品及其制备方法和应用,其以菊苣粉、青梅粉、桑叶粉、栀子粉、平卧菊三七粉及土茯苓粉作为原料制得的制品,有效减少尿酸的生成,促进痛风石的溶解。
专利CN201510252129.6公开了一种预防和治疗痛风及高尿酸血症的复合超微粉及其制备方法,采用金钗石斛、束花石斛、芡实、薏苡仁、葛根、荷叶、肉桂作为原料,采用超微粉制备技术得到的产品,能够有效降低患者血尿酸的含量,缓解疼痛。
专利CN202210405514.X公开了一种防治高血尿酸症和痛风性关节炎的产品及其制备方法,包括以下原料:天然植物粉末,低聚糖,肽粉,能够有效降低血清尿素氮、血尿酸、血肌酐,减轻痛风性关节疼痛,降低高血尿酸症和痛风性关节炎的发生。
但现有技术中制备得到的产品,防治高血尿酸症和痛风性关节炎的效果有限,无法从根本上减少尿酸的生成,并且现有技术没有同时具有降低尿酸以及抗疲劳药物存在,因此,亟需找到一种治疗效果好,副作用低的替代药物。
发明内容
有鉴于此,本发明的目的之一在于提供一种灵芝益智仁海洋鱼低聚肽组合物,其特征在于,所述组合物包含:
海洋鱼低聚肽 200-400份;
灵芝子实体 50-150份;
益智仁粉 50-100份;
姜黄粉 20-80份
栀子粉20-80份;
酸樱桃粉 20-80份;
维生素C 10-30份;
天然香料 100-200份;
酸度调节剂 100-250份;
抗性糊精 20-80份;
忧遁草提取物 10-30份;
槐米粉 20-80份;
水果粉 20-80份;
植物乳杆菌20-80份;
其中植物乳杆菌含量为100-400亿CFU/g。
本发明中的原料以及益生菌均从商业途径购买。
优选地,灵芝益智仁海洋鱼低聚肽组合物包含或为:海洋鱼低聚肽 300份;
天然香料 100份;
灵芝子实体 100份;
益智仁粉 80份;
姜黄粉 50份
栀子粉50份;
酸樱桃粉 50份;
维生素C 25份;
天然香料 100份;
酸度调节剂 200份;
抗性糊精 50份;
忧遁草提取物 20份;
槐米粉 50份;
水果粉 55份;
植物乳杆菌50份;
其中植物乳杆菌含量为250亿CFU/g。
优选地,所述天然香料为芹菜籽提取物、核桃壳提取物、香叶提取物和苏合香提取物中的一种或多种,优选地,各个提取物之间质量配比为1:1。所述水果粉为椰子粉、甜橙粉和苹果粉等中的一种或多种,水果粉主要用于调节口感,可以根据口味需要进行选择。所述酸度调节剂为柠檬酸钾、柠檬酸钠、柠檬酸和苹果酸中的一种或多种。所述植物乳杆菌可以为灭活或非灭活形式,具体地,植物乳杆菌为植物乳杆菌La10。
所述植物乳杆菌La10,其分类命名为Lactiplantibacillus plantarum,被保藏在广东省微生物菌种保藏中心,保藏编号为GDMCC No:63605,保藏时间为2023年6月30日,保藏单位地址为广州市先烈中路100号大院59号楼5楼,广东省科学院微生物研究所。
经过长时间的探索和研究,申请人意外的发现,单独采用灵芝益智仁海洋鱼低聚肽组合物中的一种或多种组分均无法预防和/或治疗高尿酸血症和/或疲劳,而本发明特定含量的灵芝益智仁海洋鱼低聚肽组合物却表现出较好的疗效,并且治疗效果优于阳性对照苯溴马隆药剂组。
因此,本发明的另一个目的在于提供包含所述的灵芝益智仁海洋鱼低聚肽组合物的组方。
具体地,所述的组方的剂型包括但不限于粉剂、片剂、丸剂、颗粒剂、胶囊剂、溶液剂、乳剂、混悬剂、油剂。进一步具体地,所述的组方的剂型为粉剂。具体地,所述的组方中包括医学上可接受的载体。进一步具体地,所述的载体包括但不限于赋性剂、缓冲剂、乳化剂、稳定剂、稀释剂、粘合剂、防腐剂。再进一步具体地,所述赋性剂选自微晶纤维素、乳糖、预胶化淀粉、环糊精、羧甲基纤维素中的至少一种。再进一步具体地,所述缓冲剂选自磷酸二氢钠、碳酸氢钠、碳酸氢铵、醋酸钠、枸橼酸盐、琥珀酸盐中的至少一种。再进一步具体地,所述乳化剂选自硬脂酸镁、硬脂酸锌、硬脂酸钙、硬脂酸甘油酯、山梨坦异硬脂酸酯、山梨坦油酸酯、甘油油酸酯中的至少一种。再进一步具体地,所述稳定剂选自金合欢胶、琼脂、藻酸、纤维素醚、羧甲基甲壳酯中的至少一种。再进一步具体地,所述稀释剂选自赤藓糖醇、甘露醇、山梨糖醇、木糖醇、乳糖、蔗糖、玉米淀粉、马铃薯淀粉、磷酸钙、柠檬酸钙中的至少一种。再进一步具体地,所述粘合剂选自乙醇、淀粉浆、羟丙基甲基纤维素、羧甲基纤维素钠、海藻酸钠、聚乙烯吡咯烷酮中的至少一种。
本发明的另一个目的在于提供所述的灵芝益智仁海洋鱼低聚肽组合物或上述组合物在制备预防和/或治疗受试者高尿酸血症和/或抗疲劳中的应用。
本发明治疗对象可以为任何哺乳动物,优选地,受试者为大鼠、小鼠、兔子、猴或人。
本发明预防和/或治疗通过改善血清尿酸(UA)、血清和肝脏黄嘌呤氧化酶活性(XOD)、血清肌酐(CRE)、血清尿素氮(BUN)、血清谷丙转氨酶(ALT)、血清谷草转氨酶(AST)水平中的一种或多种实现。本发明的预防和/或治疗还可以通过调解肠道菌群实现。
本发明首次提供一种灵芝益智仁海洋鱼低聚肽组合物(样品组),发现其在降低尿酸水平方面有较好的效果,同时该组合物还具有较好的抗疲劳效果,治疗后小鼠血清尿酸(UA)、血清和肝脏黄嘌呤氧化酶活性(XOD)、血清肌酐(CRE)、血清尿素氮(BUN)、血清谷丙转氨酶(ALT)、血清谷草转氨酶(AST)水平与模型组相比,均得到明显改善。16S RNA肠道菌群丰度分析结果表明,低剂量样品组与模型组以及高剂量样品组与模型组之间有明显的分离,表明样品能够调节高尿酸血症小鼠肠道菌群丰度。将灵芝益智仁海洋鱼低聚肽组合物开发成为具有治疗预防和/或治疗受试者高尿酸血症和/或疲劳的产品具有重要意义。
附图说明
图1为给药前后小鼠体重变化图。
图2 是样品对血清尿酸水平影响图。
图3为样品对血清黄嘌呤氧化酶活性影响图。
图4为样品对肝脏黄嘌呤氧化酶活性影响图。
图5为样品对血清肌酐水平影响图。
图6为样品对血清尿素氮水平影响图。
图7为样品对血清谷丙转氨酶(ALT)活性影响图。
图8为样品对血清谷草转氨酶(AST)活性影响图。
图9为样品对小鼠的肠道菌群丰度影响图。图中,C表示正常组,M表示模型组,LS和HS分别表示低剂量样品组和高剂量样品组。
图10为样品对小鼠抗疲劳能力评估图。
图中,不同字母代表两者具体显著性差异(P<0.01)。
具体实施方式
下面结合实施例,更具体地说明本发明的内容。应该理解,本发明的实施并不局限于下面的实施例,对本发明所做的任何形式上的变通和/或改变都落入本发明保护范围。实施例中未注明具体条件的实施方法,通常按照常规条件中所述的条件或按照制造厂商所建议的条件。实施例使用的原料、试剂以及试剂盒等均通过商业途径购买获得。
本发明实施例中所用灵芝益智仁海洋鱼低聚肽组合物样品含量包含:海洋鱼低聚肽 300g;灵芝子实体 100g;益智仁粉80g;姜黄粉50g;栀子粉50g;酸樱桃粉 50g;维生素C25g;天然香料 100g酸度调节剂 200g;抗性糊精 50g;忧遁草提取物 20g;槐米粉 50g;椰子粉 55g;植物乳杆菌La10 50g,含量为250亿CFU/g,其中,天然香料为芹菜籽提取物、核桃壳提取物、香叶提取物和苏合香提取物按照质量比1:1:1:1混合而成,酸度调节剂为柠檬酸钾和柠檬酸钠按照质量比1:1混合而成。
剂量选择:本实验设低和高2 个给药剂量组,分别为100 mg/kg,LS和200 mg/kg,HS。
本研究中涉及的动物实验经海南大学动物伦理委员会批准,使用的雄性C57 BL/J小鼠购买于湖南斯莱克景达实验动物有限公司,许可证号SCXK(湘)2019-0004。小鼠在规定的SPF级(无特殊病原体)环境中饲养,温度保持在25±2℃,湿度为60-70%,每12小时进行明暗交替。通过灌胃腺嘌呤和氧嗪酸钾(PO)的方法建立高尿酸血症小鼠模型(Cui等人,2023)。腺嘌呤为尿酸的前体物质;PO为尿酸氧化酶的化学抑制剂,可抑制小鼠体内尿酸酶的活性,使尿酸无法分解,导致体内尿酸水平上升,最终造成小鼠高尿酸血症。
适应性喂养7天后,小鼠被随机分为5组(n=6):对照组(Control),高尿酸血症模型组(Model),苯溴马隆药剂(50mg/kg)阳性对照组(Ben),低剂量样品组(100 mg/kg,LS)和高剂量样品组(200 mg/kg, HS)。高尿酸血症模型组、苯溴马隆药剂阳性对照组、低剂量样品组和高剂量样品组连续21天给予2 mL溶解于生理盐水中的建模药物(PO 200 mg/kg+腺嘌呤50 mg/kg),而对照组给予无药物的生理盐水。建模药物给药后6 h,小鼠被灌胃对应剂量的阳性药物或样品(溶解于2 mL生理盐水),对照组被灌胃生理盐水作为对照。
样品采集:最后一次给药后,小鼠被禁食16小时,期间收集小鼠粪便并储存在-80℃冰箱用于小鼠肠道菌群丰度分析。通过摘眼取血法收集小鼠的血液样本。获得的血液在4℃冰箱中静置3小时后离心(3000 rpm,4℃),提取上层血清并储存在-80℃冰箱用于生化指标的测试。将小鼠肝脏取出后用预冷的PBS清洗,并放入液氮速冻。
根据试剂盒的说明书测试了小鼠血清尿酸(UA)、血清黄嘌呤氧化酶活性(XOD)、血清肌酐(CRE)、血清尿素氮(BUN)、血清谷丙转氨酶(ALT)、血清谷草转氨酶(AST)以及肝脏黄嘌呤氧化酶活性(XOD)等指标。试剂盒购买自南京建成生物工程研究所。血清样本可以直接用于检测,肝脏组织样品需加入PBS(质量(g):体积(mL)=1:9)进行研磨,离心得到的上清液供试。
收集四组小鼠(n = 5)的粪便样本用于16S rRNA基因测序。高通量测序方法和数据处理如Deng等人(2023)所述,所有的所有组的粪便样本的DNA均使用EZNA土壤DNA试剂盒提取。采用Nanodrop对DNA进行定量,并通过1.2%琼脂糖凝胶电泳检测DNA提取质量。使用引物338F (5’-ACTCCTACGGGAGGCAGCAG-3’)和806R (5’-GGACTACHVGGGTWTCTAAT-3’)对细菌基因的可变区域V3-V4区进行扩增。PCR产物经过纯化后用Illumina公司的TruSeq NanoDNA LT Library Prep Kit测序。高通量测序结果按照报告中的分析流程进行后续分析。
分析流程:
1) 首先对高通量测序的原始下机数据根据序列质量进行初步筛查;对问题样本进行重测、补测。
2) 通过质量初筛的原始序列按照index和Barcode信息,进行文库和样本划分,并去除barcode序列。
3) 按照QIIME2 dada2分析流程或Vsearch软件的分析流程进行序列去噪或OTU聚类。
4) 对各样本(组)在不同物种分类学水平的具体组成进行展示,了解整体概况。
5) 根据ASV/OTU在不同样本中的分布,评估每个样本的Alpha多样性水平,并通过稀疏曲线反映测序深度是否合适。
6) 在ASV/OTU层面,计算各样本的距离矩阵,并通过多种非监督的排序、聚类手段,结合相应统计学检验方法,衡量不同样本(组)间的beta多样性差异及差异显著性。
7) 在物种分类学组成层面,通过各种非监督、监督的排序、聚类和建模手段,结合相应统计学检验方法,进一步衡量不同样本(组)间的物种丰度组成差异,并尝试寻找标志物种。
8) 根据物种在各样本中的组成分布,构建关联网络,计算拓扑指数,并尝试找出关键物种。
9) 根据16S rRNA、18S rRNA和ITS基因测序结果预测样本的菌群代谢功能,找出差异通路,并获得特定通路的物种组成。
10) 在以上结果的基础上,绘制具备图表,并进行统计检验分析。
根据何双等人(2009)报道的方法:在实验末期,评估实验小鼠的抗疲劳能力,在小鼠尾部固定5%体重的铅块,使其在深水(30 cm×30 cm×30 cm)中游泳直至力竭,记录小鼠游泳时间,以评估小鼠的抗疲劳能力。
为了全面了解测试样品对高尿酸血症小鼠的治疗效果及机理,本研究使用试剂盒法测试了小鼠血清尿酸(UA)、血清和肝脏黄嘌呤氧化酶活性(XOD)、血清肌酐(CRE)、血清尿素氮(BUN)、血清谷丙转氨酶(ALT)、血清谷草转氨酶(AST)水平等指标。
图1为给药前后小鼠体重变化图。给药前,与模型组相比,苯溴马隆组、低、高剂量样品组的体重均无显著性差异。给药后,各组小鼠在实验结束后的体重组间差异具有统计学意义(P<0.01)。说明测试样品在本试验条件下对动物的体重有明显影响,并且呈计量依赖性。结果见图1。
图2 是样品对血清尿酸水平影响图。由图2可知,模型组血清尿酸水平显著升高,而苯溴马隆组、低、高剂量样品组均可以显著降低血清尿酸水平,并且高剂量样品组与阳性对照组效果相当。
图3为样品对血清黄嘌呤氧化酶活性影响图。由图3可知,与模型组相比,样品组可显著降低血清黄嘌呤氧化酶活性,说明样品组可以通过降低血清黄嘌呤氧化酶活性达到降低尿酸水平的作用。
图4为样品对肝脏黄嘌呤氧化酶活性影响图。由图4可知,与模型组相比,样品组可显著降低肝脏中黄嘌呤氧化酶活性,说明样品组可以通过降低肝脏黄嘌呤氧化酶活性达到降低尿酸水平的作用。
图5为样品对血清肌酐水平影响图。由图5可知,与模型组相比,样品组可显著降低血清肌酐水平,并且高剂量样品组比阳性对照组效果更好,说明样品组可以通过降低血清肌酐水平达到降低尿酸水平的作用。
图6为样品对血清尿素氮水平影响图。由图6可知,与模型组相比,样品组可以显著降低血清尿素氮水平,说明样品组可以通过降低血清肌酐水平达到降低尿酸水平的作用,但是降低血清尿素氮的效果没有阳性对照组强,说明本申请的样品与阳性对照药机理存在差异。
图7为样品对血清谷丙转氨酶(ALT)活性影响图。由图7可知,与模型组相比,样品组可以显著降低血清谷丙转氨酶(ALT)活性,说明样品组可以通过降低谷丙转氨酶(ALT)活性水平达到降低尿酸水平的作用。
图8为样品对血清谷草转氨酶(AST)活性影响图。由图8可知,与模型组相比,样品组可以显著降低血清谷草转氨酶(AST)活性,说明样品组可以通过降低血清谷草转氨酶(AST)活性水平达到降低尿酸水平的作用。
图9为样品对小鼠的肠道菌群丰度影响图。采用16sRNA测序,对小鼠的肠道菌群丰度进行分析,由图9可知,结果表面,模型组与正常组表明高尿酸血症与肠道菌群丰度变化有一定相关性,低剂量样品组与模型组以及高剂量样品组与模型组之间有明显的分离,表明样品能够调节高尿酸血症小鼠肠道菌群丰度。图中,C表示正常组,M表示模型组,LS和HS分别表示低剂量样品组和高剂量样品组。
图10为样品对小鼠抗疲劳能力评估图。由图10可知,样品组可以显著增加模型组的力竭时间。也即样品不仅具有降低尿酸水平的作用,同时还具有促进小鼠抗疲劳的效果。
总之,给予样品治疗后,小鼠体重、血清尿酸(UA)、血清和肝脏黄嘌呤氧化酶活性(XOD)、血清肌酐(CRE)、血清尿素氮(BUN)、血清谷丙转氨酶(ALT)、血清谷草转氨酶(AST)等水平得到明显改善。16S RNA肠道菌群丰度分析结果表明,低剂量样品组与模型组以及高剂量样品组与模型组之间有明显的分离,表明样品能够调节高尿酸血症小鼠肠道菌群丰度。同时样品还具有抗疲劳的效果。将灵芝益智仁海洋鱼低聚肽组合物开发成为具有治疗预防和/或治疗受试者高尿酸血症和/或疲劳的产品具有重要意义。
申请人声明通过上述实施实例来说明本发明的产品、用途及其使用方式,但本发明并不局限于上述详细用途或使用方式,即不意味着本发明必须依赖上述详细用途和使用方式才能实验。所属技术领域的人员应该明了,对本发明的任何改进,对本发明产品各原料的等效替换及辅助成分的添加,具体方式的选择等,均落在本发明的保护范围和公开范围之内。
Claims (10)
1.一种灵芝益智仁海洋鱼低聚肽组合物,其特征在于,所述组合物包含:
海洋鱼低聚肽 200-400份;
灵芝子实体 50-150份;
益智仁粉 50-100份;
姜黄粉 20-80份;
栀子粉20-80份;
酸樱桃粉 20-80份;
维生素C 10-30份;
酸度调节剂 100-250份;
天然香料 100-200份;
抗性糊精 20-80份;
忧遁草提取物 10-30份;
槐米粉 20-80份;
水果粉 20-80份;
植物乳杆菌20-80份;
其中植物乳杆菌含量为100-400亿CFU/g。
2.如权利要求1所述的灵芝益智仁海洋鱼低聚肽组合物,其特征在于,所述组合物包含:
海洋鱼低聚肽 300份;
灵芝子实体 100份;
益智仁粉 80份;
姜黄粉 50份;
栀子粉50份;
酸樱桃粉 50份;
维生素C 25份;
天然香料 100份;
酸度调节剂 200份;
抗性糊精 50份;
忧遁草提取物 20份;
槐米粉 50份;
水果粉 55份;
植物乳杆菌50份;
其中植物乳杆菌含量为250亿CFU/g。
3.权利要求1-2任一项所述的灵芝益智仁海洋鱼低聚肽组合物,其特征在于,所述天然香料为芹菜籽提取物、核桃壳提取物、香叶提取物和苏合香提取物中的一种或多种,所述水果粉为椰子粉、甜橙粉和苹果粉中的一种或多种。
4.权利要求1-2任一项所述的灵芝益智仁海洋鱼低聚肽组合物,其特征在于,所述酸度调节剂为柠檬酸钾、柠檬酸钠、柠檬酸和苹果酸中的一种或多种。
5.权利要求1-2任一项所述的灵芝益智仁海洋鱼低聚肽组合物,所述植物乳杆菌为植物乳杆菌La10,所述植物乳杆菌La10的保藏编号为GDMCC No:63605。
6.包含权利要求1-2任一项所述的灵芝益智仁海洋鱼低聚肽组合物的组方,所述组方为片剂、粉剂或液体制剂。
7.权利要求1-5任一项所述的灵芝益智仁海洋鱼低聚肽组合物或权利要求6所述的组方在制备预防和/或治疗受试者高尿酸血症和/或疲劳药物中的应用。
8.如权利要求7所述的应用,其特征在于,所述受试者为哺乳动物。
9.如权利要求7所述的应用,其特征在于,所述预防和/或治疗通过改善血清尿酸(UA)、血清和肝脏黄嘌呤氧化酶活性(XOD)、血清肌酐(CRE)、血清尿素氮(BUN)、血清谷丙转氨酶(ALT)、血清谷草转氨酶(AST)水平中的一种或多种实现。
10.如权利要求7所述的应用,其特征在于,所述预防和/或治疗通过调解肠道菌群实现。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311336501.2A CN117100836B (zh) | 2023-10-16 | 2023-10-16 | 一种灵芝益智仁海洋鱼低聚肽组合物及其在预防或治疗高尿酸症及抗疲劳的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311336501.2A CN117100836B (zh) | 2023-10-16 | 2023-10-16 | 一种灵芝益智仁海洋鱼低聚肽组合物及其在预防或治疗高尿酸症及抗疲劳的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN117100836A true CN117100836A (zh) | 2023-11-24 |
CN117100836B CN117100836B (zh) | 2024-01-26 |
Family
ID=88798640
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311336501.2A Active CN117100836B (zh) | 2023-10-16 | 2023-10-16 | 一种灵芝益智仁海洋鱼低聚肽组合物及其在预防或治疗高尿酸症及抗疲劳的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117100836B (zh) |
Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130302310A1 (en) * | 2011-01-21 | 2013-11-14 | Jilin Zixin Pharmaceutical Research Institution LLC | Pharmaceutical Composition for Relieving Fatigue and Preparation Method Thereof |
CN104543680A (zh) * | 2015-01-23 | 2015-04-29 | 绍兴上虞宏晟技术转让服务有限公司 | 一种抗疲劳、改善胃肠功能的保健食品及其制备方法 |
CN105029447A (zh) * | 2015-08-11 | 2015-11-11 | 湖南科尔生物技术有限公司 | 一种含有活性益生菌的海洋鱼低聚肽粉 |
CN105341570A (zh) * | 2015-10-14 | 2016-02-24 | 哈尔滨工业大学 | 系列忧遁草功能性饮料及其制备方法 |
CN108042653A (zh) * | 2017-12-19 | 2018-05-18 | 广州净派保洁消毒用品有限公司 | 一种抗疲劳醒神植物棉片及其制备工艺 |
CN108498783A (zh) * | 2018-06-18 | 2018-09-07 | 马南行 | 一种治疗高尿酸血症的组合物及其制备方法 |
CN109010788A (zh) * | 2018-09-12 | 2018-12-18 | 江西天元药业有限公司 | 改善睡眠及尿频尿急夜尿频多症的组合物与制备工艺 |
CN110038119A (zh) * | 2019-04-28 | 2019-07-23 | 杭州泽健医药科技有限公司 | 一种具有降尿酸和抗疲劳作用的药物组合物 |
CN110420293A (zh) * | 2019-07-31 | 2019-11-08 | 天津尖峰弗兰德医药科技发展有限公司 | 治疗高尿酸血症和痛风的植物组合物及植物组合物固体颗粒 |
CN111887370A (zh) * | 2020-08-17 | 2020-11-06 | 广州优蓝海洋生物科技有限公司 | 一种降尿酸海洋鱼低聚肽壳寡糖固体饮料 |
CN112121144A (zh) * | 2020-09-20 | 2020-12-25 | 武汉宏博云智生物科技有限公司 | 一种刺梨组合物及其制备方法和用途 |
CN112263669A (zh) * | 2020-09-21 | 2021-01-26 | 康美华大基因技术有限公司 | 一种用于缓解高尿酸血症的低聚肽中药益生菌复合物 |
CN112458027A (zh) * | 2020-12-16 | 2021-03-09 | 江南大学 | 一株格氏乳杆菌及其缓解和治疗高尿酸血症的用途 |
CN114736946A (zh) * | 2022-06-10 | 2022-07-12 | 广东海洋大学 | 兼具抗疲劳与降尿酸的海洋鱼类低聚肽的制备方法及应用 |
CN115317574A (zh) * | 2022-08-19 | 2022-11-11 | 狮子洋生物科技(广州)有限公司 | 一种用于治疗高尿酸血症的组合物及其应用 |
-
2023
- 2023-10-16 CN CN202311336501.2A patent/CN117100836B/zh active Active
Patent Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130302310A1 (en) * | 2011-01-21 | 2013-11-14 | Jilin Zixin Pharmaceutical Research Institution LLC | Pharmaceutical Composition for Relieving Fatigue and Preparation Method Thereof |
CN104543680A (zh) * | 2015-01-23 | 2015-04-29 | 绍兴上虞宏晟技术转让服务有限公司 | 一种抗疲劳、改善胃肠功能的保健食品及其制备方法 |
CN105029447A (zh) * | 2015-08-11 | 2015-11-11 | 湖南科尔生物技术有限公司 | 一种含有活性益生菌的海洋鱼低聚肽粉 |
CN105341570A (zh) * | 2015-10-14 | 2016-02-24 | 哈尔滨工业大学 | 系列忧遁草功能性饮料及其制备方法 |
CN108042653A (zh) * | 2017-12-19 | 2018-05-18 | 广州净派保洁消毒用品有限公司 | 一种抗疲劳醒神植物棉片及其制备工艺 |
CN108498783A (zh) * | 2018-06-18 | 2018-09-07 | 马南行 | 一种治疗高尿酸血症的组合物及其制备方法 |
CN109010788A (zh) * | 2018-09-12 | 2018-12-18 | 江西天元药业有限公司 | 改善睡眠及尿频尿急夜尿频多症的组合物与制备工艺 |
CN110038119A (zh) * | 2019-04-28 | 2019-07-23 | 杭州泽健医药科技有限公司 | 一种具有降尿酸和抗疲劳作用的药物组合物 |
CN110420293A (zh) * | 2019-07-31 | 2019-11-08 | 天津尖峰弗兰德医药科技发展有限公司 | 治疗高尿酸血症和痛风的植物组合物及植物组合物固体颗粒 |
CN111887370A (zh) * | 2020-08-17 | 2020-11-06 | 广州优蓝海洋生物科技有限公司 | 一种降尿酸海洋鱼低聚肽壳寡糖固体饮料 |
CN112121144A (zh) * | 2020-09-20 | 2020-12-25 | 武汉宏博云智生物科技有限公司 | 一种刺梨组合物及其制备方法和用途 |
CN112263669A (zh) * | 2020-09-21 | 2021-01-26 | 康美华大基因技术有限公司 | 一种用于缓解高尿酸血症的低聚肽中药益生菌复合物 |
CN112458027A (zh) * | 2020-12-16 | 2021-03-09 | 江南大学 | 一株格氏乳杆菌及其缓解和治疗高尿酸血症的用途 |
CN114736946A (zh) * | 2022-06-10 | 2022-07-12 | 广东海洋大学 | 兼具抗疲劳与降尿酸的海洋鱼类低聚肽的制备方法及应用 |
CN115317574A (zh) * | 2022-08-19 | 2022-11-11 | 狮子洋生物科技(广州)有限公司 | 一种用于治疗高尿酸血症的组合物及其应用 |
Non-Patent Citations (4)
Title |
---|
CHIH-YU CHIEN 等: "Supplementation of Lactobacillus plantarum (TCI227) Prevented Potassium-Oxonate-Induced Hyperuricemia in Rats", NUTRIENTS, vol. 14, no. 22, pages 1 - 15 * |
林娜 等: "药食两用中药在痛风防治中的研究进展", 食品与药品, vol. 24, no. 2, pages 173 * |
林恋竹 等: "神秘果树叶提取物降尿酸作用及其有效成分鉴定", 中国食品学报, vol. 18, no. 1, pages 270 - 277 * |
钱丽丽 等: "试论中医缓解体力疲劳保健食品的特色", 山西中医, vol. 25, no. 3, pages 51 * |
Also Published As
Publication number | Publication date |
---|---|
CN117100836B (zh) | 2024-01-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wang et al. | Probiotic Paenibacillus polymyxa 10 and Lactobacillus plantarum 16 enhance growth performance of broilers by improving the intestinal health | |
CA3201874A1 (en) | Lactobacillus compositions and methods for prevention and treatment of microbial infection | |
EP3432899B1 (en) | Use of probiotics in the treatment and/or prevention of psoriasis | |
CN115109734B (zh) | 一株具有缓解高尿酸功能敏捷乳杆菌b13t4及其应用 | |
EP4112716A1 (en) | Lactobacillus helveticus strain and composition containing same for prevention or treatment of inflammatory diseases | |
CN106943423A (zh) | 具有调节肠道菌群结构作用的多糖组合物及其应用 | |
CN115975880A (zh) | 一株发酵粘液乳杆菌cyq09及其应用 | |
KR20130002545A (ko) | 신규한 유산균 및 이를 포함하는 당뇨병 예방 및 치료용 조성물 | |
CN113322216A (zh) | 一种副干酪乳杆菌b111h及其在代谢综合征中的应用 | |
WO2005030230A1 (en) | Compositions and methods for treatment or prevention of psoriasis and related disorders | |
CN114164130A (zh) | 一种降嘌呤前体的益生菌株、组合物及其应用 | |
CN117100836B (zh) | 一种灵芝益智仁海洋鱼低聚肽组合物及其在预防或治疗高尿酸症及抗疲劳的应用 | |
CN117899133A (zh) | 一种苣荬菜黄酮类提取物在防治溃疡性结肠炎中的应用 | |
US20210121538A1 (en) | Interactional Biosystem | |
CN116694534A (zh) | 一种长双歧杆菌sx-1326及其应用 | |
CN110156910A (zh) | 酵母葡聚糖提取物、组合物及在制备预防便秘制剂中的应用 | |
CN115191607A (zh) | 一种植物乳杆菌yu28菌株及其应用 | |
CN113274478B (zh) | 一种治疗痛风的中药发酵制剂及其制备方法 | |
US20230293601A1 (en) | Use of bacillus coagulans bc198 or its metabolites for prevention or adjuvant treatment of intestinal lesion-related pathological changes or flora imbalance caused by chemotherapy | |
Martínez‐Puig et al. | Long‐term effects on the digestive tract of feeding large amounts of resistant starch: a study in pigs | |
CN109718254A (zh) | 颤杆菌克属在预防或治疗高原病药物中的应用 | |
JP6489752B2 (ja) | 酪酸産生菌保有非ヒト動物モデル及びその作製方法 | |
CN114832004B (zh) | 一种治疗代谢异常的药物组合物及其制备方法 | |
CN112155205B (zh) | 一种降血压组合物及其制备方法与应用 | |
CN110090230B (zh) | 凝结芽孢杆菌在制备预防或治疗胆管癌制剂中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |